- Evidence: Nature Biotechnology（2021）

- Product: OncoCompass^® Series

- Description：

In 2021, the prototype of OncoCompass^® was showcased in Nature Biotechnology, highlighting its exceptional performance in comparison to other leading liquid assays. Subsequently, the standard version (HS) was developed for regulatory approval in China.

In 2024, OncoCompass^® underwent a significant upgrade to its ultra-deep version (HS-UMI), incorporating unique molecular identifiers (UMI) technology to facilitate the ultra-low frequency detection of SNVs, Indels, fusions and CNVs. The enhanced technology features an exceptional cell-free DNA (cfDNA) conversion rate and a comprehensive approach to minimize false calls. Additionally, an extensive validation process across a diverse range of cancer types ensures detection accuracy and reliability.

- Evidence: Nature Biomedical Engineering (2021) &Annals of Oncology (2023)

- Product: OverC™, OverC™ Monitor

- Description:

The key technology underlies the OverC™ test is ELSA-seq, a high-resolution methylation profiling tool characterized by well-preserved molecular diversity, effective noise suppression and robust high-dimensional modelling. In 2021, the technical principle of ELSA-seq™ was published in Nature Biomedical Engineering. This approach combines a novel targeted methylation sequencing method, single-molecule-based pattern recognition, and machine learning to capture highly diluted cancer signals in circulation. The results highlight the potential use of machine-learning-aided deep methylation sequencing for noninvasive detection of cancer at early stages. Subsequently, its performance was validated in lung, colorectal, liver, esophageal, ovarian, and pancreatic cancer, singly.

- Evidence：Cancer Cell (2023)

- Product：CanCatch^® PROPHET

- Description：

CanCatch™ PROPHET is powered by an advanced technology known as brPROPHET, which encompasses comprehensive whole-exome tumor profiling, peprsonalized probe design, and UMI-aided ultra-deep sequencing (HS-UMI) techniques. In 2023, the MEDAL study, published in Cancer Cell, underscored the exceptional performance of brPROPHET. This pioneering assay stands out for its early detection of lung cancer relapse with an extraordinary sensitivity rate of 0.004%, demonstrating superior sensitivity and reliability compared to other mutation tracking methods.